SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors upcoming FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date and the companys amended application emphasizing upper-limb function data. Bullish traders interpret the longer-term data, rare-disease policy discussions and recent commercial hiring as encouraging signs, while skeptics cite prior FDA concerns and say approval remains uncertain.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

The rally toward fresh highs is drawing attention ahead of the expected Q3 report, with traders weighing BRIUMVIs growth against unconfirmed buyout speculation and possible short-covering. Some see the move as a bet on earnings and the companys commercial prospects rather than an acquisition; no deal has been confirmed.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could fall after early 2027 has fueled a sharp selloff and concern about future pricing and revenue. Traders disagree over whether the warning signals sustained pressure or is only a preliminary estimate, pointing to CMSs more stable outlook while criticizing CorMedixs lack of clarification.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a sharp Nasdaq selloff tied to weakness in technology and semiconductor stocks, with traders debating whether concerns about AI spending and earnings justify more downside or whether the decline is an oversold dip to buy. The late-session rebound prompted some dip-buying optimism, but bearish traders continued to warn that the correction may not be over.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 AML trial reaching its prespecified 80th death event has triggered final analysis, with topline results expected this quarter. Traders are divided over whether GPS improved survival: bullish holders see the pending readout as a major catalyst, while bears question the efficacy case, and the share-price decline has intensified debate about selling pressure and alleged short activity.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens PAPZIMEOS commercial launch and stronger-than-expected quarterly results, including a move to profitability, are driving bullish discussion about its growth prospects. Traders also debate whether potential INO-3107 competition could challenge PAPZIMEOS and whether heavy short interest is amplifying the stocks moves.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 76,874.98691422 USD and is down -4.82 over the last 24 hours. It is currently trading on 12773 active market(s) with $58,826,736,014.03 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

A reported major Binance security breach and temporary withdrawal suspension have fueled Bitcoin selling and concerns about crypto exchange security. Traders disagree over whether the incident signals broader risk or is isolated to Binance, with some viewing the pullback as a buying opportunity and others warning of further downside.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

ARM is drawing attention amid a steep pullback from its highs, with traders citing semiconductor weakness, profit-taking and concerns that its valuation assumes years of strong AI-driven growth. Bulls point to potential data-center CPU demand and ARMs role in AI infrastructure, while bears question whether growth can justify the premium; the upcoming earnings report is a focus.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its quarterly report is fueling concern about slowing ad growth, analyst target cuts, and weakness across advertising-related stocks. Traders debate whether the decline reflects deteriorating prospects or has overshot the companys growth and cash-generation fundamentals, with earnings seen as a key test.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

A sharp selloff in silver and other precious metals is driving attention, with inflation concerns tied to higher energy prices and expectations of tighter interest rates weighing on the market. Traders are split between calling the decline a continuing routsometimes alleging manipulationand seeing oversold conditions as a possible buying opportunity.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amalgamated Financial (AMAL) Q3 Earnings and Revenues Top Estimates

Amalgamated Financial (AMAL) delivered earnings and revenue surprises of +5.56% and +2.50%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Oversold Conditions For SLR Investment (SLRC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

SLR Investment (SLRC) Misses Q2 Earnings and Revenue Estimates

SLR Investment (SLRC) delivered earnings and revenue surprises of -2.94% and -0.43%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Slr Investment Enters Oversold Territory

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics strong fundamentals and a valuation that looks inexpensive...

SLR Investment (NASDAQ:SLRC) Announces Earnings Results, Misses Expectations By $0.07 EPS

SLR Investment (NASDAQ:SLRC - Get Free Report) issued its quarterly earnings results on Tuesday. The financial services provider reported $0.33 EPS for the quarter, missing analysts' consensus estimates of $0.40 by ($0.07). The company had revenue of $47.14 million during the quarter, compared to...

SLR Investment (NASDAQ:SLRC) Shares Gap Down  on Disappointing Earnings

SLR Investment (NASDAQ:SLRC) Shares Gap Down on Disappointing Earnings...

SLR Investment Corp. (NASDAQ:SLRC) Declares Quarterly Dividend of $0.31

SLR Investment Corp. (NASDAQ:SLRC) announced a quarterly dividend on Tuesday, May 5th. Shareholders of record on Friday, June 12th will be paid a dividend of 0.31 per share by the financial services...

SLR Investment (SLRC) Lags Q1 Earnings and Revenue Estimates

SLR Investment (SLRC) delivered earnings and revenue surprises of -17.50% and -8.92%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

SLR Investment (SLRC) to Release Quarterly Earnings on Tuesday

SLR Investment (NASDAQ:SLRC) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 5. (View Earnings Report at...

SLR Investment (NASDAQ:SLRC) Shares Pass Above 200-Day Moving Average   - Here's What Happened

SLR Investment (NASDAQ:SLRC) Stock Passes Above Two Hundred Day Moving Average - Time to Sell...

SLR Investment Corp. engages in investing directly and indirectly in senior secured loans of private middle market companies to generate current income that is distributed to shareholders quarterly. It focuses on the investment of leveraged middle-market companies in the form of senior secured loans, financing leases, and to a lesser extent, unsecured loans, and equity securities. The company was founded in February 2007 and is headquartered in NY, New York.

SLR Investment Corp

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$11.63
Prev Close	$11.79
Open	$11.72
Dividend Yield	10.61%
50-Day Moving Average	$11.89
Beta	0.58
Avg. Volume	376,230.09
PE Ratio	8.72

52-Week High	$16.36
52-Week Low	$10.96
Market Capitalization	$643.2M
EPS (Annual)	$1.70
Price to Book	0.65
Revenue Per Employee	N/A

Feed

News

Sentiment

Earnings

Fundamentals

Info

SLRC Fundamentals